Company Overview
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Why Investors Should Care
Revenue has grown at a 12.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $72.10K (+0.0% YoY); net profit $-4.23M.
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.19% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -78.32% |
| 6 Months: | -55.43% |
| 3 Months: | -63.58% |
| 1 Month: | -38.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)22.19 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.2% over 5 years.
CONS
- Trading 81.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 22 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SILO Silo Pharma, Inc. PHARMA | 2.28 | -0.61 | $4.00M | 0.00% | -61.55% | -91.23% | 12.19% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2012 | Jun 2012 | Sep 2012 | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 268 | 294 | 2.22K | 16.29K | 47.43K | 68.08K | - | - | 18.02K | 18.02K | 18.03K | 18.02K | 18.02K | 18.03K | 18.02K | 18.02K | - | 18.03K | 18.02K | 18.02K | 18.03K | 18.03K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46K | 1.46K | 20.69K | 20.69K | 20.69K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 186 | 210 | 883 | -13.16K | 16.56K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | 16.57K | - | 16.57K | 16.57K | -2.66K | -2.66K | -2.66K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.11M | 1.27M | 1.15M | 783.86K | 1.59M |
| Operating Income | - | - | - | - | - | - | -134.85K | -76.11K | -81.18K | -174.56K | -189.87K | -242.51K | -159.36K | -996.69K | -558.89K | -901.14K | -436.85K | -463.94K | -527.26K | -494.29K | -949.15K | -803.49K | -1.11M | -773.40K | -879.51K | -1.00M | -1.01M | - | -1.09M | -1.25M | -1.15M | -786.52K | -1.59M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.03M | -1.20M | -1.11M | -845.89K | -1.64M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.07K | 1.65K | 886 | 32.70K | 3.37K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.03M | -1.20M | -1.11M | -881.53K | -1.65M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -13.04K | -5.67K | -8.55K | -22.88K | -22.48K | -5.74K | 17.55K | -315.91K | -198.16K | -123.52K | -242.21K | -265.48K | -238.88K | -1.38M | -633.79K | -930.70K | -461.99K | 6.39M | -604.07K | -658.40K | -983.25K | -906.40K | -1.01M | -660.16K | -801.67K | -931.78K | -928.81K | - | -1.03M | -1.20M | -1.11M | -881.53K | -1.65M |
| Diluted EPS | - | - | - | - | - | - | 0.00 | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 | - | - | -0.01 | 0.00 | 0.00 | 3.16 | 0.00 | - | -0.49 | -0.29 | -0.32 | -0.21 | -0.28 | -0.31 | -0.22 | - | -3.45 | -2.85 | -1.80 | - | -1.80 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.60K | 98.85K | 70.51K | 170.28K | 105.68K | 375.80K | 202.91K | 130.72K | 174.50K | 318.24K | 392.82K | 517.55K | - | 593.96K | 717.25K | 543.62K | - | 1.01M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 40.57K | 40.92K | - | 72.10K | 72.10K | 72.10K | 72.10K |
| Cost of Revenue | - | - | - | - | - | - | - | 5.84K | 5.84K | 5.84K | 44.30K |
| Gross Profit | - | - | - | - | 13.18K | -135.20K | - | 66.26K | 66.26K | 66.26K | 27.81K |
| Operating Expenses | - | - | - | - | - | - | - | 3.71M | 3.92M | 4.77M | 4.31M |
| Operating Income | - | - | -490.87K | -594.24K | -930.40K | -2.20M | - | -3.65M | -3.86M | -4.71M | -4.28M |
| EBITDA | - | - | - | - | - | - | - | -3.91M | -3.63M | -4.38M | -4.18M |
| Interest Expense | - | - | - | - | - | - | - | 2.20K | 4.87K | 5.08K | 37.30K |
| Pretax Income | - | - | - | - | - | - | - | -3.91M | -3.63M | -4.39M | -4.23M |
| Tax Provision | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -49.80K | -39.45K | 356.54K | -969.46K | -1.01M | -3.04M | - | -3.91M | -3.70M | -4.39M | -4.23M |
| Diluted EPS | - | - | 0.01 | -0.02 | - | -0.05 | - | -25.65 | -18.00 | -17.85 | -7.50 |
| R&D Expense | - | - | - | - | - | 26.25K | 693.91K | 1.29M | 845.09K | 2.37M | 2.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.48K | 1.75K | 279 | 2.21M | - | 1.64M | 855.42K | 493.85K | 1.43M | - | 11.64M | 7.75M | 7.41M | 7.61M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 11.57M | 7.68M | 7.11M | 7.39M |
| Cash & Equivalents | 0 | 47.48K | 1.75K | 279 | 2.01M | 579.21K | 294.59K | 336.68K | 111.75K | 1.13M | - | 11.37M | 3.52M | 3.91M | 4.75M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 0 | 66.01K | 0 | - | - |
| Total Liabilities | - | - | 3.50K | 41.47K | 18.72K | - | - | - | 116.74K | 145.97K | - | 1.30M | 1.57M | 2.38M | 1.30M |
| Current Liabilities | - | 0 | 3.50K | 25.69K | - | - | 38.34K | 47.98K | 116.74K | 141.72K | - | 436.32K | 775.59K | 1.66M | 650.18K |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | - | 47.48K | -1.75K | -41.19K | 1.79M | 846.51K | 1.20M | 407.44K | -22.89K | 1.28M | - | 10.34M | 6.18M | 5.03M | 6.31M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 210.59K | 210.61K | 298.96K | 887.88K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -46.30K | -21.47K | -181.61K | -284.62K | 272.64K | -794.32K | -1.16M | - | -3.50M | -3.22M | -3.83M | -4.66M |
| Investing Cash Flow | - | - | - | - | -250.00K | 186.74K | 39.00K | - | 86.71K | -4.15M | 973.78K | 644.02K |
| Financing Cash Flow | 575 | 20.00K | 2.19M | - | 19.45K | 382.66K | 2.13M | - | 4.94M | -471.12K | 3.24M | 4.86M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | - | -574.92K |
| Free Cash Flow | - | - | - | - | - | - | - | - | -3.50M | -3.22M | -3.83M | -5.24M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 1.53M | -7.84M | 381.49K | 842.90K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 32.5% | -330.4% | - | 91.9% | 91.9% | 91.9% | 38.6% |
| Operating Margin % | - | - | - | - | -2,293.4% | -5,380.2% | - | -5,059.0% | -5,347.4% | -6,526.4% | -5,937.0% |
| Net Margin % | - | - | - | - | -2,497.7% | -7,422.5% | - | -5,420.9% | -5,132.6% | -6,092.6% | -5,863.5% |
| ROE % | 2,849.1% | 95.8% | 29.6% | -237.9% | 4,426.4% | -237.2% | - | -37.8% | -59.9% | -87.3% | -67.0% |
| ROCE % | - | - | -30.6% | -73.6% | -246.7% | -171.3% | - | -32.5% | -55.3% | -81.8% | -61.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AdvisorShares Investments, LLC | 4.76% | 75.58K | $139.07K |
| 2 | FNY Investment Advisers, LLC | 2.36% | 37.51K | $69.01K |
| 3 | Citadel Advisors Llc | 1.06% | 16.80K | $30.91K |
| 4 | Vanguard Capital Management LLC | 0.75% | 11.96K | $22.00K |
| 5 | Vanguard Fiduciary Trust Co | 0.06% | 874 | $1.61K |
| 6 | Tower Research Capital LLC (TRC) | 0.01% | 181 | $333 |
| 7 | IFP Advisors, Inc | 0.01% | 175 | $322 |
| 8 | Harbour Investments, Inc. | - | 14 | $25 |
| 9 | Citigroup Inc. | - | 1 | $1 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SILO
Silo Pharma Stock Price Forecast. Should You Buy SILO? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5GQmlWT3h3UmJYWmNZUC1jX0ZRcmtaUDNoYXkwQmgtSVVLR2loY19yUUhncVRVdS1oNm1QdzJ3dFp4ZktiUTd3bQ?oc=5" target="_blank">Silo Pharma Stock Price Forecast. Should You Buy SILO?</a>  …
Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPdUVsSm1qc2p3bksxMV85Z2tRUzU5ckF2cGxUa01CRjNtbnFRYWlzZ0RZdHp2Z1dtMHMyOXpURi1IMllicjQzZHUyZlB0aW5zR0QzZk5ZWXR2Rmx3bnJmLXJsRXpFbFdwTk4tZS1Qdk9rS2M2UmN3Wm02WTRsb2xEejNoM1Z1WjU4cVdlbz…
AMD Cloud Credits Support QwikAgents' Persistent AI Agents - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPWV9YWVVvYTdXd3hCQXpFUllnVm1vbkhfR0l4QnZGSUhlZWs5SEJzSnVicUN3MzhGY0VxMEpJTUREOUJZUzZfY002UnhWczJFaFBFWHBPRmczUGp1dHlFTmV4SDB2MElONTdDYU0xcjRuMmhGTWxfb29NVEhPV19yRUlsUGxXcG9oSzN4QT…
Why Did SILO Stock Soar 85% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNTXN5QmpOU041bGR6OU9oOGxGa1V5V3BRb1FHd1FZbXZWbWlaOEZ0ZHAteGFvU25qdU9QOHpFNktIT2c5T0NEZTF3YXl0ckVhWXJWYzZVelE4LVZPbGNZYXZrNzVKQ3U5c2VzNlhQRUxqLW9zamVDTy1yYVdyVHlnYnhVenVTMFF6N2hWTT…
Silo Pharma Acquires Digital Assets via Stock Issuance - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaHdzbmdNYUM3bk9KNmpBalpldTVudG1YaWlmU2pkalRzcnYxZnlEUmRNaW1SQ3RfYmsybkUxUkV2X05oLXp2dko3OTlCanlHTXQzMElyRTZzOVF2RnZNQ0Y3amxoNDRfZW9DdDVObU5lai0yeElHMzJKTWRFREFHd3RBTGlicG1PVjZuVW…
Silo Pharma Inc (NYSE: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE5HaGRoMEZBSm5hd3l3YkxzWUUxY3F6dWxXTkdwS3NzRTNtcTRHZ29DUUZFbXJjUzJVRTh2QU5tSDloYlA5TVlQUmlQN0RsNWVRNDcw?oc=5" target="_blank">Silo Pharma Inc (NYSE: SILO) Share Price, SILO Stock Ne…
SILO — Frequently Asked Questions
What is the current share price of Silo Pharma, Inc. (SILO)?
As of 2026-09-19 21:16 PDT, Silo Pharma, Inc. (SILO) trades at $2.28 on NasdaqCM. Its 52-week range is $2.28 to $12.22.
What is the market capitalisation of SILO?
Silo Pharma, Inc. (SILO) has a market capitalisation of $4.00M on NasdaqCM.
What is the P/E ratio of SILO?
SILO trades at a trailing price-to-earnings (P/E) ratio of -0.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.43.
What is the return on equity (ROE) of SILO?
SILO has a return on equity (ROE) of -91.23%. Its return on capital employed (ROCE) is -61.55%.
Is SILO a good stock to buy?
This page provides a data-driven analysis of Silo Pharma, Inc. (SILO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.